AcquisitionsJun 4, 2026, 07:33 AM
SciSparc Subsidiary NeuroThera Acquires 54% of CliniQuantum for CAD$9.46M
AI Summary
SciSparc Ltd. announced that its majority-owned subsidiary, NeuroThera Labs Inc., completed the acquisition of approximately 54% interest in CliniQuantum Ltd. The transaction involved NeuroThera issuing 56,600,000 common shares, valued at approximately CAD$9,459,954.20. Additionally, the selling shareholders may receive up to US$2,500,000 in earn-out payments contingent on achieving certain milestones, including patent filings and fundraising. CliniQuantum specializes in applying quantum simulation to clinical trial data analysis to improve precision.
Key Highlights
- NeuroThera Labs Inc., SciSparc's majority-owned subsidiary, acquired approximately 54% interest in CliniQuantum Ltd.
- The acquisition involved the issuance of 56,600,000 NeuroThera common shares, valued at approximately CAD$9,459,954.20.
- Selling Shareholders are eligible for earn-out payments of up to US$2,500,000.
- Earn-out payments include US$500,000 for each of the first three patent applications, up to US$1,500,000.
- An additional earn-out of 7.0% of certain fundraising proceeds, up to US$1,000,000, is also possible.
- CliniQuantum holds an exclusive, worldwide license for quantum simulation and Monte Carlo methods in clinical trials.
Price Impact
More from SPRC